Literature DB >> 29917046

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan.   

Abstract

Entities:  

Year:  2018        PMID： 29917046     DOI： 10.1093/annonc/mdy162

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  117 in total

Review 1.  A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Authors:  Amir Jazaeri; Robert L Coleman; Anil K Sood; Michael M Frumovitz; Pamela T Soliman; Aaron Shafer; Jeffry J Cutrera; Marlana Klinger; Sara E Sharafi; Cynae A L Johnson; Valerie F Villanueva; Emily M Hinchcliff; Andrea Dickens; Katherine E Cain; Jaime E Anderson; Karen H Lu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2018-09-10       Impact factor: 5.482

Review 2.  Mechanisms of checkpoint inhibition-induced adverse events.

Authors:  P Urwyler; I Earnshaw; M Bermudez; E Perucha; W Wu; S Ryan; L Mcdonald; S N Karagiannis; L S Taams; N Powell; A Cope; S Papa
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

Review 3.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

Review 4.  Adverse events associated with immune checkpoint inhibitor treatment for cancer.

Authors:  Khashayar Esfahani; Nicholas Meti; Wilson H Miller; Marie Hudson
Journal:  CMAJ       Date:  2019-01-14       Impact factor: 8.262

Review 5.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

6.  Diagnosis and Management of Rare Immune-Related Adverse Events.

Authors:  Sara R Schoenfeld; Mary E Aronow; Rebecca Karp Leaf; Michael Dougan; Kerry L Reynolds
Journal:  Oncologist       Date:  2019-11-06

7.  Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.

Authors:  Michael Li; Jordan S Sack; Osama E Rahma; F Stephen Hodi; Stephen D Zucker; Shilpa Grover
Journal:  Cancer       Date:  2020-09-05       Impact factor: 6.860

Review 8.  Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Authors:  Petros Fessas; Lucia A Possamai; James Clark; Ella Daniels; Cathrin Gudd; Benjamin H Mullish; James L Alexander; David J Pinato
Journal:  Immunology       Date:  2019-11-19       Impact factor: 7.397

9.  [Supportive therapy and management of side effects in dermato-oncology].

Authors:  Laura von Dücker; Svea Hüning; Katharina Kähler; Patrick Terheyden; Do Ro Thée Nashan
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

Review 10.  Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon.

Authors:  Beth A Helmink; Christina L Roland; Colleen M Kiernan; Jennifer A Wargo
Journal:  Ann Surg Oncol       Date:  2020-01-21       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.